211 related articles for article (PubMed ID: 8555515)
1. Surveillance methods for central venous access device-associated infections in Canadian pediatric hospitals.
Langley JM; LaRoche L; Hanakowski M
Can J Infect Control; 1995; 10(3):80-2. PubMed ID: 8555515
[TBL] [Abstract][Full Text] [Related]
2. Central venous access device-related infections in patients with haemophilia.
Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
[TBL] [Abstract][Full Text] [Related]
3. Central venous access devices site care practices: an international survey of 34 countries.
Broadhurst D; Moureau N; Ullman AJ
J Vasc Access; 2016; 17(1):78-86. PubMed ID: 26349858
[TBL] [Abstract][Full Text] [Related]
4. Central venous Access device SeCurement And Dressing Effectiveness (CASCADE) in paediatrics: protocol for pilot randomised controlled trials.
Ullman AJ; Kleidon T; Gibson V; Long DA; Williams T; McBride CA; Hallahan A; Mihala G; Cooke M; Rickard CM
BMJ Open; 2016 Jun; 6(6):e011197. PubMed ID: 27259529
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.
Ragni MV; Journeycake JM; Brambilla DJ
Haemophilia; 2008 Jan; 14(1):30-8. PubMed ID: 18005145
[TBL] [Abstract][Full Text] [Related]
6. Device-associated nosocomial infections in limited-resources countries: findings of the International Nosocomial Infection Control Consortium (INICC).
Rosenthal VD
Am J Infect Control; 2008 Dec; 36(10):S171.e7-12. PubMed ID: 19084148
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients.
Simon A; Fleischhack G; Hasan C; Bode U; Engelhart S; Kramer MH
Infect Control Hosp Epidemiol; 2000 Sep; 21(9):592-6. PubMed ID: 11001263
[TBL] [Abstract][Full Text] [Related]
8. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit.
Costello JM; Morrow DF; Graham DA; Potter-Bynoe G; Sandora TJ; Laussen PC
Pediatrics; 2008 May; 121(5):915-23. PubMed ID: 18450894
[TBL] [Abstract][Full Text] [Related]
9. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
10. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
[TBL] [Abstract][Full Text] [Related]
11. Central venous access devices in haemophilia.
Valentino LA; Ewenstein B; Navickis RJ; Wilkes MM
Haemophilia; 2004 Mar; 10(2):134-46. PubMed ID: 14962202
[TBL] [Abstract][Full Text] [Related]
12. Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial.
Ullman AJ; Kleidon T; Gibson V; McBride CA; Mihala G; Cooke M; Rickard CM
BMC Cancer; 2017 Aug; 17(1):595. PubMed ID: 28854967
[TBL] [Abstract][Full Text] [Related]
13. [Surveillance of nosocomial infections: prospective study in a pediatric intensive care unit. Background, patients and methods].
Simon A; Bindl L; Kramer MH
Klin Padiatr; 2000; 212(1):2-9. PubMed ID: 10719676
[TBL] [Abstract][Full Text] [Related]
14. Central venous access and handwashing: variability in policies and practices.
Galway R; Harrod ME; Crisp J; Donnellan R; Hardy J; Harvey A; Maurice L; Petty S; Senner A
Paediatr Nurs; 2003 Dec; 15(10):14-8. PubMed ID: 14705353
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of infectious complications associated with central venous access devices in children with haemophilia.
Tarantino MD; Lail A; Donfield SM; Lynn H; Peddle L; Hunsberger S; Shapiro AD
Haemophilia; 2003 Sep; 9(5):588-92. PubMed ID: 14511299
[TBL] [Abstract][Full Text] [Related]
16. Pediatric central venous access devices: practice, performance, and costs.
Ullman AJ; Gibson V; Takashima MD; Kleidon TM; Schults J; Saiyed M; Cattanach P; Paterson R; Cooke M; Rickard CM; Byrnes J; Chopra V
Pediatr Res; 2022 Nov; 92(5):1381-1390. PubMed ID: 35136199
[TBL] [Abstract][Full Text] [Related]
17. Road map for improvement: Point prevalence audit and survey of central venous access devices in paediatric acute care.
Ullman AJ; Cooke M; Kleidon T; Rickard CM
J Paediatr Child Health; 2017 Feb; 53(2):123-130. PubMed ID: 27709723
[TBL] [Abstract][Full Text] [Related]
18. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
19. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
[TBL] [Abstract][Full Text] [Related]
20. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
